BHAVESH BALAR, MD
Hematology & Oncology Physician · FREEHOLD, NJ
Individual Active NPI 1134113376
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 1,422 | 457,749.1 | $34,410,965 | $9,932,448 | $7,916,033 |
| 2023 | 1,209 | 395,002 | $27,444,014 | $9,263,283 | $7,363,736 |
| 2022 | 977 | 417,467.4 | $19,192,950 | $9,209,062 | $7,352,322 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 67,140 | $3 | $2 |
| J9271 | Injection, pembrolizumab, 1 mg | 40,600 | $56 | $45 |
| J9299 | Injection, nivolumab, 1 mg | 23,080 | $31 | $25 |
| J1627 | Injection, granisetron, extended-release, 0.1 mg | 18,500 | $6 | $4 |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 15,840 | $50 | $40 |
| J0897 | Injection, denosumab, 1 mg | 15,300 | $26 | $21 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 13,500 | $0 | $0 |
| J1437 | Injection, ferric derisomaltose, 10 mg | 13,300 | $20 | $16 |
| J0185 | Injection, aprepitant, 1 mg | 11,570 | $2 | $1 |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 9,420 | $0 | $0 |
| J1453 | Injection, fosaprepitant, 1 mg | 7,500 | $0 | $0 |
| J9267 | Injection, paclitaxel, 1 mg | 6,023 | $0 | $0 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Hematology & Oncology Physician | 207RH0003X | ✓ | 25MA07783700 | NJ |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Hematology & Oncology Physician providers in New Jersey
- NPI 1952356198
- NPI 1922101161
- NPI 1003181074
- NPI 1255412359
- NPI 1285194969
- NPI 1619059987
- NPI 1518165919
- NPI 1659542702
See all Hematology & Oncology Physician providers in New Jersey →
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.